CapsoVision Q3 revenue $3.5M (+19% YoY); FDA submission for pancreatic cancer capsule

CapsoVision, Inc

2025-Q3 EPS reported -$1.05 revenue$9,636,000

Revenue $3.5M (+19% YoY); new accounts up 31%; CapsoCam Plus used by 151k patients.
Gross profit $1.9M (+16%); gross margin 54% vs 56% in Q3 2024.
Operating expenses $9.9M (+$2.5M) driven by Canon CMOS development and public company costs.
Cash $17.8M; July 2025 IPO net proceeds $23.4M.
Submitted FDA Breakthrough Device Designation for early-stage pancreatic cancer detection; David Garcia appointed SVP Finance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.